A study investigating the efficacy and safety of anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma

Update Il y a 4 ans
Reference: EUCTR2012-003650-88

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Test the superiority of anetumab ravtansine monotherapy over vinorelbine in progression-free survival (PFS)


Inclusion criteria

  • Patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin